VENTRICULAR to their susceptibility to treatment by procaine amide.1 The usual report has been that in ventricular tachycardia procaine amide has been used successfully after the failure of relatively large doses of quinidine, with either oral or intravenous use of the latter drug. Claggett2 has recently compiled results of the intravenous use of quinidine from 15 authors on 62 cases of ventricular tachycardia and found that in 42 of these cases there was reversion to sinus rhythm with the use of quinidine in intervals ranging from 30 minutes to 21 days from the beginning of treatment. Claggett has a comprehensive bibliography on the oral and intravenous use of quinidine appended to his report.
The present report concerns a recurrent form of ventricular tachycardia which could not be controlled adequately with recommended oral doses of procaine amide, although it was temporarily controlled with procaine amide given intravenously. The patient
CHAPMAN RA. USE OF QUINIDINE SULFATE AND OF PROCAINE AMIDE IN A PATIENT WITH PAROXYSMAL VENTRICULAR TACHYCARDIA. AMA Arch Intern Med. 1952;90(1):90–95. doi:10.1001/archinte.1952.00240070096010
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: